Description:

Registration Breast Cancer CALGB 40503 NCT00601900 Registration Breast Cancer CALGB 40503 REGISTRATION WORKSHEET - 2551888v1.0 NCT00601900 CALGB 40503 REGISTRATION WORKSHEET Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=24089B14-3CCA-485C-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=24089B14-3CCA-485C-E044-0003BA3F9857

Keywords:
Versions (3) ▾
  1. 12/18/14
  2. 1/9/15
  3. 7/25/15
Uploaded on:

July 25, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Registration Breast Cancer CALGB 40503 NCT00601900

Endocrine Therapy in Combination with Anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy plus for Women with Hormone Receptor-Positive Advanced Breast Cancer

Header Module
Protocol Administration
MM DD YYYY
MM DD YYYY
Patient Demographics/pre-treatment Characteristics
MM.DD.YYYY
Gender
Race (Mark all that apply)
Ethnicity (Mark one)
Patient Demographics/pre-treatment Characteristics2
Performance Status (ECOG/Zubrod scale)
cm
kg
Method of Payment (Adminstration USA only Mark one)
Certification Of Eligibility And Protocol Design
In the opinion of the investigator, is the patient eligible?
Planned endocrine therapy
Disease Free Interval (months from initial diagnosis to first progression)
Is measurable disease present?
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use for research on the patient's cancer?
Patient's initial consent given for specimen use for genetic research relating to the study treatment
Patient's Initial Consent given for specimen kept for future use in research to learn about, prevent, or treat cancer
Patient's initial consent given for specimen(s) may be kept for use in research to learn about, prevent, or treat other health problems (for example: diabetes, Alzheimer's disease, or heart disease)
Patient's initial consent given for further contact to participate in research on future studies
Registration Information

Similar models